# ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Source: https://onco.cc/trials/nct06328738/  
OnCo record `nct06328738` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ELVN-002 run by Enliven Therapeutics, active and no longer recruiting.

## Summary

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer is a phase 1 interventional study registered as NCT06328738 by Enliven Therapeutics, with 275 participants planned, started 2024-05-30. Conditions recorded: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification and Colorectal Cancer. Interventions recorded: ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel and Leucovorin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06328738
- Phase: 1
- Setting: A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer
- Sponsor: Enliven Therapeutics
- Enrolled: 275

## Sources

- ClinicalTrials.gov NCT06328738: https://clinicaltrials.gov/study/NCT06328738

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [ELVN-002](https://onco.cc/drugs/elvn-002/)
- companies: [Enliven Therapeutics](https://onco.cc/companies/enliven-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06328738.json